PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING
申请人:enEvolv, Inc.
公开号:EP3027754A1
公开(公告)日:2016-06-08
COMPOUNDS FOR USE IN ANTI-CANCER IMMUNOTHERAPY
申请人:Sirenas LLC
公开号:US20220226281A1
公开(公告)日:2022-07-21
The present disclosure relates to the reversal of T cell exhaustion using aplysiatoxin analogs or PKC theta agonist compounds for anti-cancer immunotherapy. The treatment with aplysiatoxin analogs or PKC theta agonist compounds improve the anti-tumour activity of a T cell, inducing a NFAT-dependent T cell activation, increasing the pool of immune-checkpoint inhibitor responsive T cells, increasing lymphocyte infiltration and increasing the population of activated CD4+ and/or CD8+ cells. The methods of the present disclosure provide treatment of tumors and infections.